#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Temporal trends in breast cancer survival by race and ethnicity: A population-based cohort study


Autoři: Deirdre A. Hill aff001;  Eric R. Prossnitz aff002;  Melanie Royce aff001;  Andrea Nibbe aff001
Působiště autorů: Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, United States of America aff001;  Department of Molecular Medicine, University of New Mexico, Albuquerque, New Mexico, United States of America aff002
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0224064

Souhrn

Introduction

Differences in breast cancer survival by race and ethnicity are often assumed to be a fairly recent phenomenon, and are hypothesized to have arisen due to gaps in receipt of screening or therapy. The emergence of these differences in calendar time have implications for identification of their origin. We sought to determine whether breast cancer survival differences by race or ethnicity arose in tandem with the advent of screening or therapeutic advances.

Materials and methods

A cohort of women diagnosed with invasive breast cancer from 1975–2009 in 18 population-based registries were followed for five-year breast cancer cause-specific survival. Differences in survival according to race/ethnicity and estrogen receptor status were quantified in Cox proportional hazards models, with estimation of hazard ratios (HR), 95% confidence intervals (CI), and absolute risk differences. For 2010, we also assessed differences in survival by breast cancer subtypes defined by hormone receptor and Her2/neu status.

Results

Among over 930,000 women, initial differences in five-year breast cancer-specific survival by race became apparent among 1975–1979 diagnoses and continued to be evident, with stronger disparities apparent in those of Black vs. White Non-Hispanic (WNH) race and among estrogen-receptor positive vs. negative disease. Within breast cancer subtype, all included race/ethnic groups experienced disparate survival in comparison with WNH women for triple-negative disease. Black women had a consistent gap in absolute survival of .10-.12, compared with WNH women, from 1975–1979 through all included time periods, such that 5- year survival of Black women diagnosed in 2005–09 lagged more than 20 years behind that of WNH women.

Discussion

Survival differed by race for diagnoses that predate the introduction of mammographic screening and most therapeutic advances. Absolute differences in survival by race and ethnicity have remained almost constant over 40 years of observation, suggesting early origins for some contributors.

Klíčová slova:

Breast cancer – Cancer detection and diagnosis – Cancer treatment – Estrogens – Ethnic epidemiology – Ethnicities – Hispanic people – Oncology


Zdroje

1. Mandelblatt JS, Sheppard VB, Neugut AI (2013) Black-white differences in breast cancer outcomes among older Medicare beneficiaries: does systemic treatment matter? Jama 310: 376–377. doi: 10.1001/jama.2013.8273 23917286

2. Silber JH, Rosenbaum PR, Clark AS, Giantonio BJ, Ross RN, et al. (2013) Characteristics associated with differences in survival among black and white women with breast cancer. Jama 310: 389–397. doi: 10.1001/jama.2013.8272 23917289

3. van Ravesteyn NT, Schechter CB, Near AM, Heijnsdijk EAM, Stoto MA, et al. (2011) Race-specific impact of natural history, mammography screening, and adjuvant treatment on breast cancer mortality rates in the United States. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20: 112–122.

4. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA (2015) Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA 313: 165–173. doi: 10.1001/jama.2014.17322 25585328

5. Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, et al. (2015) Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. J Clin Oncol 33: 2254–2261. doi: 10.1200/JCO.2014.57.1349 25964252

6. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1975–2015). National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission.

7. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, et al. (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134: e48–72. doi: 10.1043/1543-2165-134.7.e48 20586616

8. Sparano JA, Wang M, Zhao F, Stearns V, Martino S, et al. (2012) Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. Journal of the National Cancer Institute 104: 406–414. doi: 10.1093/jnci/djr543 22250182

9. O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, et al. (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16: 6100–6110. doi: 10.1158/1078-0432.CCR-10-1533 21169259

10. Ma H, Lu Y, Malone KE, Marchbanks PA, Deapen DM, et al. (2013) Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status. BMC Cancer 13: 225. doi: 10.1186/1471-2407-13-225 23642215

11. DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A (2017) Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 67: 439–448. doi: 10.3322/caac.21412 28972651

12. Neugut AI, Zhong X, Wright JD, Accordino M, Yang J, et al. (2016) Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer. JAMA Oncol 2: 1326–1332. doi: 10.1001/jamaoncol.2016.1291 27281650

13. Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21: 602–606. doi: 10.1200/JCO.2003.07.071 12586795

14. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, et al. (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28: 4120–4128. doi: 10.1200/JCO.2009.25.9655 20585090

15. Hershman DL, Tsui J, Wright JD, Coromilas EJ, Tsai WY, et al. (2015) Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer. J Clin Oncol 33: 1053–1059. doi: 10.1200/JCO.2014.58.3062 25691670

16. Biggers A, Shi Y, Charlson J, Smith EC, Smallwood AJ, et al. (2016) Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy. J Clin Oncol 34: 4398–4404. doi: 10.1200/JCO.2016.67.3350 27998232

17. Hill DA FS, Lomo L, Wiggins C, Barry M, Prossnitz E, Royce M. (2017) Breast cancer survival, survival disparities, and guideline‑based treatment. Breast Cancer Res Treat.

18. Albain KS, Unger JM, Crowley JJ, Coltman CA Jr., Hershman DL (2009) Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. Journal of the National Cancer Institute 101: 984–992. doi: 10.1093/jnci/djp175 19584328

19. Hershman DL, Unger JM, Barlow WE, Hutchins LF, Martino S, et al. (2009) Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27: 2157–2162.

20. Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, et al. (2017) Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. JAMA Oncol 3: 1654–1662. doi: 10.1001/jamaoncol.2017.0595 28472234


Článek vyšel v časopise

PLOS One


2019 Číslo 10
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

KOST
Koncepce osteologické péče pro gynekology a praktické lékaře
nový kurz
Autoři: MUDr. František Šenk

Sekvenční léčba schizofrenie
Autoři: MUDr. Jana Hořínková

Hypertenze a hypercholesterolémie – synergický efekt léčby
Autoři: prof. MUDr. Hana Rosolová, DrSc.

Svět praktické medicíny 5/2023 (znalostní test z časopisu)

Imunopatologie? … a co my s tím???
Autoři: doc. MUDr. Helena Lahoda Brodská, Ph.D.

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#